Machine learning programme used to predict stem cell growth

Drug Target Review | November 21, 2019

Researchers have used a computational model to learn how to manipulate stem cell arrangement, including those that may eventually be useful in generating personalised organs. According to the team, their discovery could be used to develop model organs grown from a patient’s own cells, which could ‘revolutionise’ how diseases are treated by increasing disease understanding or testing drugs. The study was conducted by a team from Gladstone Institutes, in collaboration with Boston University, both US. Induced pluripotent stem (iPS) cells, similar to the stem cells found in an embryo, have the potential to become nearly every type of cell in the body. Although researchers can prompt these cells into differentiating into specific organ cells, they cannot grow into functioning three-dimensional (3D) organs. “Despite the importance of organisation for functioning tissues, we as scientists have had difficulty creating tissues in a dish with stem cells,” said Ashley Libby, co-first author. “Instead of an organised tissue, we often get a disorganised mix of different cell types.”

Spotlight

For Rady School of Management alum Julio de Unamuno (MBA ’14) the idea for his company, Lab Fellows, came from questioning the status quo of the biotech industry and the process of drug development. He identified a key problem for biotech startups – access to expensive lab equipment that can facilitate groundbreaking discoveries. While in the Rady School’s Lab to Market course, de Unamuno developed an idea to address this access gap and Lab Fellows was born.

Spotlight

For Rady School of Management alum Julio de Unamuno (MBA ’14) the idea for his company, Lab Fellows, came from questioning the status quo of the biotech industry and the process of drug development. He identified a key problem for biotech startups – access to expensive lab equipment that can facilitate groundbreaking discoveries. While in the Rady School’s Lab to Market course, de Unamuno developed an idea to address this access gap and Lab Fellows was born.

Related News

MEDTECH

Biotech Start-Up Aanika Biosciences Lands Initial $12M Funding for Cutting-Edge Food Tracing Technology

Aanika Biosciences | December 01, 2021

Biotech start-up Aanika Biosciences today announced the initial closing of its $12 million Series A round, led by Jon Cholak of Adit Ventures along with existing investors Draper Associates and SOSV. The investment will help scale the company’s food tracing technology platform, advance research and expand its Brooklyn food safety and manufacturing facility to approximately 30,000 square feet. Aanika's proprietary technology is designed to accelerate the speed and accuracy of how food safety issues are handled. The platform, which uses edible microbial ‘tags,’ has already been tested on leafy greens and has the potential to be applied to other foods and ingredients including oils, coffee, meats and grains. “Innovation in food safety is long overdue, and there couldn’t be a more important time to bring a technology like this to the market. The pandemic has truly exposed the fragility of our supply chain. Being able to expand and build out our capability will give farmers, insurers, food companies and consumers an added layer of transparency and security, as well as minimize the economic and environmental impact of food recalls.” Dr. Ellen Jorgensen, Chief Science Officer for Aanika The technology enables farmers to 'watermark' crops with edible, food-friendly microbes that can be detected at any point in the product’s journey through the supply chain, so that when there is a case of foodborne illness it can be traced directly to the source. “Foodborne illness impacts over 50 million people and costs the U.S. tens of billions of dollars a year. Our technology can help minimize the impact and we are developing solutions that may prevent it from happening in the first place,” said co-founder and CEO of Aanika, Vishaal Bhuyan. “Identifying the origin of food recalls is just the start of what this platform can do. We are excited to see how far we can push our microbial technology to add value in the form of combating contamination, increasing nutritional content and supporting crop health. We are also exploring how our technology can even revolutionize agricultural insurance underwriting. All of this is driven by the power of biology.” "We believe Aanika could transform the food system as their traceability technology can integrate with the blockchain and ensure high quality data from end-to-end,” said Tim Draper, Founder and Managing Partner of Draper Associates. About Aanika Biosciences Aanika Biosciences was co-founded in 2018 by Vishaal Bhuyan after he personally experienced the consequences of ordering fresh, ethically sourced seeds and receiving stale, contaminated products instead. He made it is his mission to create a safer food supply by finding a way to track, trace and authenticate products. Aanika’s customized microbial-based tags help companies gain valuable insights about their supply chains, help their customers make better consumption choices, and create a more sustainable world.

Read More

CELL AND GENE THERAPY

Vipergen Publishes Powerful New Drug Discovery Approach for the First Time, Screening DNA-encoded Small-molecule Libraries (DELs) Inside Living Cells

Vipergen | February 18, 2021

Vipergen ApS announced today a published study depicting a ground-breaking new medication revelation approach that empowers, interestingly, screening DNA-encoded small-molecule libraries (DELs) inside living cells. The study, published in the peer-reviewed Journal of the American Chemical Society, highlights the potential of Vipergen's Cellular Binder Trap Enrichment® (cBTE) technology to significantly grow the ability to discover novel small molecules, including against difficult-to-drug targets, and reduce attrition rates in drug discovery. Vipergen is offering its cBTE DNA-encoded library drug disclosure platform as a service to biotechnology and pharmaceutical company partners to accelerate and improve their drug discovery processes. "This research validates the potential for Vipergen's Cellular Binder Trap Enrichment platform to become a revolutionary tool in small-molecule drug discovery based on its ability to successfully screen DELs against drug targets inside living cells, with no requirement for purified active target protein," said Nils Hansen, Ph.D., Chief Executive Officer of Vipergen. "We expect the ability to perform DEL screening under the more physiologically relevant conditions of a living cell to significantly lower attrition rates in drug discovery. Furthermore, by uniquely allowing us to eliminate the requirement for highly purified active target protein, this technology will improve timelines and bring about new options for novel drug development by allowing us to screen many more targets, prioritize those giving the most promising screening results, and screen DELs against challenging targets that are difficult to express and purify in an active form. We look forward to providing this new tool to biotechnology and pharmaceutical partners to substantially improve the efficiency and success of their small-molecule drug discovery efforts." About Vipergen's Cellular Binder Trap Enrichment®(cBTE) Technology Vipergen's proprietary Cellular Binder Trap Enrichment®(cBTE) is the first and only technology for screening DNA-encoded small-molecule libraries (DELs) inside a living cell. The platform is designed to accelerate and improve the success rate for discovering novel, high-quality small molecules for drug development—including against challenging drug targets that are difficult to express and purify in an active form. About Vipergen ApS Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Vipergen provides its proprietary suite of leading-edge DEL technologies as a service to biotechnology and pharmaceutical company partners, including top pharmaceutical companies in the U.S., EU, and Japan.

Read More

INDUSTRY OUTLOOK

Sartorius Stedim Biotech Acquires U.S.-Based Purification Expert WaterSep BioSeparations LLC

Sartorius Stedim Biotech | December 10, 2020

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical business, today procured U.S.- based filtration master WaterSep BioSeparations LLC. WaterSep BioSeparations develops, makes and markets empty fiber layer gadgets and pre-cleaned congregations for upstream and downstream biopharmaceutical applications. The exclusive organization situated in Marlborough, Massachusetts, USA, employs around 15 individuals and is required to procure income of approximately 2.5 million U.S. dollars in 2020 at solid development rates and a generous twofold digit EBITDA edge. The gatherings conceded to a price tag of roughly 27 million U.S. dollars in addition to a procure out segment of up to 9 million U.S. dollars, contingent upon the accomplishment of characterized deals revenue growth by 2023. This official statement contains forward-looking articulations about the future development of the Sartorius Stedim Biotech Group. Forward-looking proclamations are liable to known and obscure dangers, vulnerabilities and different elements that could make real outcomes vary substantially from those communicated or suggested by such explanations. Sartorius Stedim Biotech accepts no risk for refreshing such articulations considering new data or future occasions. This is an interpretation of the first French-language public statement. Sartorius Stedim Biotech will not assume any risk for the accuracy of this translation. The first French official statement is the legally binding version.

Read More